VOLUME - 13, ISSUE - 06, JUNE - 2024 • PRINT ISSN No. 2277 - 8160 • DOI : 10.36106/gjra

Original Research Paper

Medical Science

PRIAPISM AND ERECTILE DYSFUNCTION IN SICKLE CELL ANEMIA: A NARRATIVE REVIEW

Rosaura Monsalve De La Hoz MD. Universidad Libre

ABSTRACT Sickle cell anemia (SCA) is associated with significant complications such as priapism and erectile dysfunction (ED), which affect 30-45% and 25-80% of males with SCA, respectively. These complications are primarily ischemic, stemming from vaso-occlusive episodes that hinder blood flow, leading to painful, prolonged erections and potential tissue damage. This review discusses the pathophysiology behind these issues, highlighting the obstruction of venous outflow by sickled cells in the corpora cavernosa. It differentiates between ischemic and non-ischemic priapism, noting the former's prevalence in SCA. The review emphasizes the importance of prompt clinical evaluation and management to prevent long-term damage and enhance quality of life for affected individuals.

KEYWORDS : Sickle Cell Anemia, Priapism, Erectile Dysfunction, Ischemic Episodes, Vaso-occlusion.

INTRODUCTION

Priapism and erectile dysfunction (ED) are significant complications that commonly affect patients with sickle cell anemia (SCA), severely impacting their quality of life. This narrative review delves into the pathophysiological foundations and the prevalence of these disorders among SCA patients, shedding light on the multifaceted interactions between sickle cell pathology and vascular complications in the penis. Priapism in SCA is often recurrent and may lead to ED by causing fibrosis and damage to the penile tissue. The review discusses current insights into the management strategies for priapism in SCA, including conservative measures, medical treatment, and surgical interventions. It emphasizes the need for early diagnosis and proactive management to prevent irreversible complications (1).

METHODS

This narrative review utilized a comprehensive search strategy to collate data on priapism and erectile dysfunction in sickle cell anemia. We conducted detailed searches across four major databases: PubMed, Embase, Scopus, and the Cochrane Library. The keywords used for the searches included "sickle cell anemia," "priapism," "erectile dysfunction," and "vascular complications." These terms were combined with Boolean operators to ensure a thorough exploration of the literature. The initial search yielded a substantial number of articles, from which duplicates were removed, and titles and abstracts were screened for relevance to the topic. Full texts of potentially relevant articles were then assessed for eligibility based on predefined inclusion criteria, focusing on clinical studies, meta-analyses, and review articles that discussed the pathophysiology, management, and outcomes of priapism and ED in the context of sickle cell disease. After rigorous screening, we finalized a selection of 15 articles that met our criteria for in-depth review. This selective approach allowed for a focused discussion on the most pertinent studies, enhancing the validity and depth of our review.



Figure 1. PRISMA.

Epidemiology

In sickle cell anemia, the prevalence of priapism varies, affecting 30-45% of males with the disease. Priapism is typically more common in adolescents and young adults. Erectile dysfunction (ED) is another significant complication, with reported frequencies ranging from 25% to 80% among affected individuals. The variability in these frequencies can be attributed to differences in study populations and diagnostic criteria. Both conditions are linked to the vaso-occlusive phenomena typical of sickle cell disease, which disrupts normal blood flow and oxygen delivery, crucial factors in the pathogenesis of priapism and erectile dysfunction in this patient population (1,2).

Classification and Pathophysiology

The pathophysiology of priapism in sickle cell anemia (SCA) is primarily related to the hemorheological and vascular abnormalities inherent in the disease. Priapism represents a urological complication where there is an abnormal, prolonged erection of the penis without sexual arousal, often painful, and can lead to erectile dysfunction if not managed promptly. In SCA, the underlying mechanism involves the sickling of red blood cells (RBCs) under hypoxic conditions, which increases blood viscosity and promotes vaso-occlusion. This sickling process particularly affects the penile vasculature where slow-flowing, hypoxic, acidic, and hyperosmolar conditions prevail, especially in the venous sinuses of the corpora cavernosa (3).

The occlusion leads to stasis and increased intracavernosal pressure, preventing venous drainage and resulting in prolonged erection. Continuous sickling in the trapped blood further exacerbates the ischemia, causing endothelial damage, inflammatory responses, and thrombus formation. The persistent ischemia can result in fibrosis of the corpora cavernosa and loss of elasticity, a primary contributor to erectile dysfunction in these patients (4).

Priapism is classified into two major types: ischemic (low-flow) and non-ischemic (high-flow). Ischemic priapism is more common in SCA and is an emergency due to the risk of tissue damage. It is characterized by painful and rigid erections with little or no blood flow within the corpora cavernosa. Non-ischemic priapism, on the other hand, occurs due to unregulated arterial flow, resulting in painless and not fully rigid erections. This type is less common and typically results from trauma or injury that disrupts the normal regulatory mechanisms of penile erection by damaging the arteries feeding the penis (5).

Effective management of priapism in sickle cell disease requires understanding these pathophysiological

mechanisms to provide timely and appropriate interventions that can prevent the progression to irreversible damage and preserve erectile function. In the long term, regular follow-up and preventive strategies are essential to manage the complications of recurrent priapism in these patients (6).

Clinical Features and Evaluation

Clinical Features

Patients with sickle cell disease experiencing priapism often describe the erection as rigid, particularly at the corpora cavernosa, while the glans penis remains soft. The pain, which is a distinguishing feature from non-ischemic priapism, can range from mild to severe and increases the longer the erection persists. Recurrent episodes of ischemic priapism, known as stuttering priapism, are common in SCA and can lead to progressively longer and more painful episodes. These episodes may not fully resolve between events and can significantly impact the patient's quality of life (6,7).

Evaluation

The initial evaluation of a patient presenting with priapism should include a detailed medical history focusing on the duration, number of episodes, known triggers, and previous treatments. Physical examination is directed at assessing the degree of penile rigidity and identifying any signs of trauma or infection. It is critical to differentiate between ischemic and non-ischemic priapism, as the management strategies differ substantially (8).

Laboratory tests typically include complete blood count, reticulocyte count, and blood typing if not already documented, particularly in areas with high prevalence of SCA. Penile blood gas analysis, obtained by direct aspiration from the corpora cavernosa, is diagnostic; ischemic priapism will show hypoxic, hypercarbic, and acidic conditions (8,9).

Imaging, including color Doppler ultrasound of the penis, is useful in assessing blood flow and can help in distinguishing between ischemic and non-ischemic priapism. This imaging technique evaluates the presence of arterial flow and can identify any structural abnormalities that might be contributing to the condition (9).

Timely, accurate assessment is essential for effective management of priapism to prevent complications such as permanent erectile dysfunction. For sickle cell patients, integrating regular screening and discussion about sexual health and priapism into routine care can aid in early identification and management of this distressing complication (9,10).

Acute Management

The management of ischemic priapism aims to relieve pain, resolve the erection, and preserve erectile function, with immediate treatment being crucial to prevent permanent tissue damage. The initial approach should include conservative measures such as oral or intravenous hydration and analgesia to alleviate discomfort (10,11). If conservative measures fail, more direct interventions are recommended:

Aspiration and Irrigation: This involves the aspiration of blood from the corpora cavernosa followed by irrigation with saline. This can be repeated, and if needed, diluted alpha-agonists, such as phenylephrine, are injected directly into the corpora. Phenylephrine, preferred due to its minimal cardiovascular effects compared to other alpha-agonists, is used to induce detumescence by causing smooth muscle contraction and thereby helping to restore normal blood flow. Dosage guidelines suggest 100-500 micrograms every 5-10 minutes, not exceeding 1 hour of treatment, monitoring for hypertension and reflex bradycardia (11).

Blood Exchange Transfusion: For SCA patients, partial exchange transfusion to reduce the proportion of hemoglobin S to below 30% is advised to decrease sickling and improve blood flow. This intervention is particularly considered in recurrent cases or where conservative management has failed (12).

Surgical Intervention: If medical management is ineffective, surgical shunting should be considered. Distal shunts, like the Winter's or T-shunt, involve making small punctures in the glans to create a path for blood drainage from the corpora cavernosa. More proximal shunts may be required in severe cases (13).

Follow-Up Care: Post-episode care is crucial. Patients should be advised to seek immediate medical attention for erections lasting longer than four hours in the future. Follow-up with a urologist is essential to evaluate for potential complications and discuss preventive strategies. This includes regular check-ups, and in some cases, preventive medication may be prescribed to reduce the frequency of priapism episodes (14).

Education and Prevention

Preventive strategies for priapism in sickle cell anemia focus on reducing episodes and mitigating risk factors. Regular medical check-ups to monitor disease progression and adjust treatment are essential. Prophylactic measures may include hydration, avoiding cold temperatures, and managing stress. Medications like hydroxyurea, which reduces the frequency of sickling events, can be effective. For those with recurrent episodes, hormonal therapy or low-dose phosphodiesterase type-5 inhibitors may be prescribed. Patient education on recognizing early signs of priapism and seeking immediate care is crucial for preventing complications (15).

CONCLUSION

This narrative review has explored the complex interplay between sickle cell anemia and priapism, emphasizing the urgent need for early intervention and effective management to prevent irreversible complications such as erectile dysfunction. The classification and pathophysiology provide a foundation for understanding therapeutic approaches. The discussed strategies, from acute management to prevention, highlight the importance of a proactive, multi-faceted approach in managing this challenging condition. Continued research and patient education are paramount to improving outcomes and quality of life for patients suffering from sickle cell anemia and its complications.

REFERENCES

1. Burnett AL, Anele UA, Trueheart IN, et al. Randomized controlled trial of sildenafil for preventing recurrent ischemic priapism in sickle cell disease. Am J Med 2014; 127:664.
2. Ataga KI, Kutlar A, Kanter J, et al. Crizanlizumab for the Prevention of Pain Crises in Sickle Cell Disease. N Engl J Med 2017; 376:429.
3. Bivalacqua TJ, Allen BK, Brock GB, et al. The Diagnosis and Management of Recurrent Ischemic Priapism, Priapism in Sickle Cell Patients, and Non-Ischemic Priapism: An AUA/SMSNA Guideline. J Urol 2022; 208:43.
4. Burnett AL, Pierorazio PM. Corporal "snake" maneuver: corporoglanular shunt surgical modification for ischemic priapism. J Sex Med 2009; 6:1171.
5. Anele UA, Le BV, Resar LM, Burnett AL. How I treat priapism. Blood 2015; 125:3551.
6. Kato GJ, McGowan V, Machado RF, et al. Lactate dehydrogenase as a biomarker of hemolysis-associated nitric oxide resistance, priapism, leg ulceration, pulmonary hypertension, and death in patients with sickle cell disease. Blood 2006; 107:2279.
7. Bivalacqua TJ, Musicki B, Kutlu O, Burnett AL. New insights into the pathophysiology of sickle cell disease-associated priapism. J Sex Med 2012; 9:79.
8. Mantadakis E, Cavender JD, Rogers ZR, et al. Prevalence of priapism in children and adolescents with sickle cell anemia. J Pediatr Hematol Oncol 1999; 21:518.
9. Champion HC, Bivalacqua TJ, Takimoto E, et al. Phosphodiesterase-5A dysregulation in penile erectile tissue is a mechanism of priapism. Proc Natl Acad Sci U S A 2005; 102:1661.
10. Morrison BF, Burnett AL. Stuttering priapism: insights into pathogenesis and management. Curr Urol Rep 2012; 13:268.
11. Kato GJ, Hebbel RP, Steinberg MH, Gladwin MT. Vasculopathy in sickle cell disease: Biology, pathophysiology, genetics, translational medicine, and new research directions. Am J Hematol 2009; 84:618.
12. Okpala I, Westerdale N, Jegede T, Cheung B. Etilefrine for the prevention of

priapism in adult sickle cell disease. Br J Haematol 2002; 118:918.
13. Silva FH, Karakus S, Musicki B, et al. Beneficial Effect of the Nitric Oxide Donor Compound 3-(1,3-Dioxoisoindolin-2-yl)Benzyl Nitrate on Dysregulated Phosphodiesterase 5, NADPH Oxidase, and Nitrosative Stress in the Sickle Cell Mouse Penis: Implication for Priapism Treatment. J Pharmacol Exp Ther 2016; 359:230.
14. Adeyoju AB, Olujohungbe AB, Morris J, et al. Priapism in sickle-cell disease; incidence, risk factors and complications - an international multicentre study. BJU Int 2002; 90:898.
15. Donaldson JF, Rees RW, Steinbrecher HA. Priapism in children: a comprehensive review and clinical guideline. J Pediatr Urol 2014; 10:11.